pamidronate has been researched along with Fracture, Pathologic in 44 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta." | 9.12 | Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. ( Choi, JH; Shin, YL; Yoo, HW, 2007) |
| "Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy." | 9.08 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, H; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, M; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, JF, 1998) |
| "Intravenous pamidronate has been used off-label in the treatment of severe osteogenesis imperfecta (OI) for almost 20 years." | 7.80 | Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. ( Bompadre, V; Sousa, T; White, KK, 2014) |
| "To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis." | 7.70 | Intravenous pamidronate in juvenile osteoporosis. ( Boivin, CM; Crabtree, NJ; Shaw, NJ, 2000) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 7.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Intermittent infusions of intravenous pamidronate would seem to be effective in both reducing turnover of bone and increasing bone density in corticosteroid induced osteoporosis associated with chronic lung disease." | 7.68 | Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. ( Anderson, K; Banham, SW; Boyle, IT; Bryden, FM; Cowan, RA; Fenner, JA; Gallacher, SJ; Logue, FC, 1992) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 6.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 6.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| "We evaluated the efficacy of a monthly infusion of pamidronate on the frequency of fractures, biochemical effects, and bone mineral density in children with osteogenesis imperfecta." | 5.12 | Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta. ( Choi, JH; Shin, YL; Yoo, HW, 2007) |
| "Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy." | 5.08 | Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, H; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, M; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, JF, 1998) |
| "Intravenous pamidronate has been used off-label in the treatment of severe osteogenesis imperfecta (OI) for almost 20 years." | 3.80 | Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy. ( Bompadre, V; Sousa, T; White, KK, 2014) |
| "Our results show that the majority of patients with breast cancer, who develop bony metastases in Newfoundland and Labrador, are initially treated with the bisphosphonate, pamidronate." | 3.79 | Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre. ( Edwards, S; Laing, K; McCarthy, J; McCrate, F; Murphy, L; Powell, E; Seal, M, 2013) |
| "The multidisciplinary, rational approach, which involves early surgical intramedullary fixation of fractures with subsequent rehabilitation and Pamidronate administration, is considered to provide a more effective therapy with better results and therefore better quality of life in patients with osteogenesis imperfecta." | 3.74 | [Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta]. ( Kokavec, M; Novorolský, K; Pribilincová, Z, 2008) |
| "To investigate the use of the aminobisphosphonate, disodium pamidronate, in children with vertebral osteoporosis." | 3.70 | Intravenous pamidronate in juvenile osteoporosis. ( Boivin, CM; Crabtree, NJ; Shaw, NJ, 2000) |
| "Inhibition of skeletal mineralisation is a well-recognized complication of disodium etidronate therapy that was identified in the earliest studies of its use in osteoporosis and Paget's disease." | 3.70 | Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease. ( MacGowan, JR; Morris, VH; Pringle, J; Stamp, TC, 2000) |
| "The successful use of pamidronate, a bisphosphonate, for the treatment of hypercalcemia and/or osteopenia is reported in three children with renal failure or following renal transplant." | 3.70 | The use of pamidronate in three children with renal disease. ( Rodd, C; Sellers, E; Sharma, A, 1998) |
| "The response to the bisphosphonate, pamidronate, is reported in a child with osteogenesis imperfecta who had recurrent symptomatic hypercalcaemia after immobilisation following fractures." | 3.69 | Hypercalcaemia in osteogenesis imperfecta treated with pamidronate. ( Ball, RJ; Smith, RA; Wilkinson, H; Williams, CJ, 1997) |
| "Intermittent infusions of intravenous pamidronate would seem to be effective in both reducing turnover of bone and increasing bone density in corticosteroid induced osteoporosis associated with chronic lung disease." | 3.68 | Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study. ( Anderson, K; Banham, SW; Boyle, IT; Bryden, FM; Cowan, RA; Fenner, JA; Gallacher, SJ; Logue, FC, 1992) |
| "One of the main features of McCune-Albright syndrome is bone fibrous dysplasia (BFD) often associated with severe clinical outcomes, such as bone pain, bone deformities and pathological fractures." | 2.72 | Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. ( Andreo, M; Bellone, J; Corrias, A; de Sanctis, C; Lala, R; Marzari, D; Matarazzo, P, 2006) |
| "Children with symptomatic pathological fractures of the axial spine or ribs were treated with pamidronate 1 mg/kg/dose (n=17) IV at 60-day intervals for 1 yr (n=15) or 2 yr (n=2)." | 2.71 | Pamidronate treatment of pediatric fracture patients on chronic steroid therapy. ( Acott, PD; Crocker, JF; Lang, BA; Wong, JA, 2005) |
| "Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions." | 2.69 | Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth? ( Dranitsaris, G, 1999) |
| " In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i." | 2.68 | The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996) |
| "There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented." | 2.66 | Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987) |
| "Bone metastases are associated with pathologic fractures, spinal cord compression, and bone pain and can require narcotics or palliative radiation for pain relief." | 2.48 | Bone-targeted agents: preventing skeletal complications in prostate cancer. ( Morgans, AK; Smith, MR, 2012) |
| "Collapsing focal segmental glomerulosclerosis is well described in its idiopathic form, mostly seen in young African American patients, and in association with HIV virus." | 2.45 | [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review]. ( Jotterand, V; Martin, PY; Moll, S; Saudan, P, 2009) |
| "Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status." | 2.41 | [Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002) |
| "Patients with breast cancer associated solely with osseous metastasis may live for a number of years." | 2.41 | Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000) |
| "The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood." | 2.39 | Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996) |
| "The medical records of 534 women with breast cancer who developed bone metastases between 1999 and 2011 were reviewed." | 1.43 | Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents. ( Fujimoto, M; Fujiwara, Y; Hashimoto, J; Hirakawa, A; Kinoshita, F; Kodaira, M; Shimizu, C; Takahashi, N; Tamura, K; Tanaka, R; Yamamoto, H; Yonemori, K; Yunokawa, M, 2016) |
| "Osteoporosis is a common complication in children with motor impairments." | 1.37 | Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders. ( Berard, C; Poirot, I; Vuillerot, C; Wagner, S, 2011) |
| "Repair of pathologic fracture can result in palliation and prolonged survival." | 1.37 | Outcome after repair of a sarcoma-related pathologic fracture in dogs: a Veterinary Society of Surgical Oncology Retrospective Study. ( Bacon, NJ; Bhandal, J; Boston, SE; Bruce, C; Cavanaugh, RP; Culp, WT; Hamilton, MH; Lincoln, JD; Liptak, JM; Scharvogel, S, 2011) |
| "SREs included radiation (79%), pathologic fractures (12%), and hypercalcemia (9%)." | 1.36 | Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting. ( Clemons, M; Dranatisaris, G; Myers, J; Simmons, C; Trinkaus, M, 2010) |
| "To find an effective symptomatic treatment for osteogenesis imperfecta (OI)." | 1.31 | Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 2002) |
| "Osteoporosis is common in patients with chronic cholestatic liver disease, and atraumatic spinal fracture is a recognized complication after orthotopic liver transplantation." | 1.30 | Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. ( Day, CP; Francis, RM; Hudson, M; Manas, DM; Reeves, HL, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.27) | 18.7374 |
| 1990's | 13 (29.55) | 18.2507 |
| 2000's | 21 (47.73) | 29.6817 |
| 2010's | 9 (20.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biggin, A | 1 |
| Munns, CF | 1 |
| Sousa, T | 1 |
| Bompadre, V | 1 |
| White, KK | 1 |
| Tanaka, R | 1 |
| Yonemori, K | 1 |
| Hirakawa, A | 1 |
| Kinoshita, F | 1 |
| Takahashi, N | 1 |
| Hashimoto, J | 1 |
| Kodaira, M | 1 |
| Yamamoto, H | 1 |
| Yunokawa, M | 1 |
| Shimizu, C | 1 |
| Fujimoto, M | 1 |
| Fujiwara, Y | 1 |
| Tamura, K | 1 |
| Kokavec, M | 1 |
| Novorolský, K | 1 |
| Pribilincová, Z | 1 |
| Aarabi, S | 1 |
| Draper, L | 1 |
| Grayson, B | 1 |
| Gurtner, GC | 1 |
| Jotterand, V | 1 |
| Moll, S | 1 |
| Martin, PY | 1 |
| Saudan, P | 1 |
| Trinkaus, M | 1 |
| Simmons, C | 1 |
| Myers, J | 1 |
| Dranatisaris, G | 1 |
| Clemons, M | 1 |
| Scoletta, M | 1 |
| Arduino, PG | 1 |
| Dalmasso, P | 1 |
| Broccoletti, R | 1 |
| Mozzati, M | 1 |
| Boston, SE | 1 |
| Bacon, NJ | 1 |
| Culp, WT | 1 |
| Bhandal, J | 1 |
| Bruce, C | 1 |
| Cavanaugh, RP | 1 |
| Hamilton, MH | 1 |
| Lincoln, JD | 1 |
| Liptak, JM | 1 |
| Scharvogel, S | 1 |
| Wagner, S | 1 |
| Poirot, I | 1 |
| Vuillerot, C | 1 |
| Berard, C | 1 |
| Morgans, AK | 1 |
| Smith, MR | 1 |
| Murphy, L | 1 |
| McCarthy, J | 1 |
| McCrate, F | 1 |
| Laing, K | 1 |
| Powell, E | 1 |
| Seal, M | 1 |
| Edwards, S | 1 |
| Nagykálnai, T | 1 |
| Landherr, L | 1 |
| Zatkóné, GP | 1 |
| Gyuricska, A | 1 |
| Heijckmann, AC | 1 |
| Juttmann, JR | 1 |
| Wolffenbuttel, BH | 1 |
| Major, PP | 1 |
| Cook, R | 1 |
| Saad, F | 1 |
| Musto, P | 1 |
| Falcone, A | 1 |
| Sanpaolo, G | 1 |
| Bodenizza, C | 1 |
| Cascavilla, N | 1 |
| Melillo, L | 1 |
| Scalzulli, PR | 1 |
| Dell'Olio, M | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Carella, AM | 1 |
| Bin-Abbas, BS | 1 |
| Al-Ashwal, AA | 1 |
| Al-Zayed, ZS | 1 |
| Sakati, NA | 1 |
| Acott, PD | 1 |
| Wong, JA | 1 |
| Lang, BA | 1 |
| Crocker, JF | 1 |
| Lala, R | 1 |
| Matarazzo, P | 1 |
| Andreo, M | 1 |
| Marzari, D | 1 |
| Bellone, J | 1 |
| Corrias, A | 1 |
| de Sanctis, C | 1 |
| Mosekilde, L | 1 |
| Vestergaard, P | 1 |
| Langdahl, B | 1 |
| Ward, KA | 1 |
| Adams, JE | 1 |
| Freemont, TJ | 1 |
| Mughal, MZ | 1 |
| Choi, JH | 1 |
| Shin, YL | 1 |
| Yoo, HW | 1 |
| Muschitz, C | 1 |
| Roschger, P | 1 |
| Patsch, J | 1 |
| Pollhammer, I | 1 |
| Koller, B | 1 |
| Klaushofer, K | 1 |
| Resch, H | 1 |
| Samuel, R | 1 |
| Katz, K | 1 |
| Papapoulos, SE | 1 |
| Yosipovitch, Z | 1 |
| Zaizov, R | 1 |
| Liberman, UA | 1 |
| Harvey, HA | 1 |
| Lipton, A | 2 |
| Williams, CJ | 1 |
| Smith, RA | 1 |
| Ball, RJ | 1 |
| Wilkinson, H | 1 |
| Adamietz, IA | 1 |
| Kanis, JA | 1 |
| Berenson, JR | 1 |
| Lichtenstein, A | 1 |
| Porter, L | 1 |
| Dimopoulos, MA | 1 |
| Bordoni, R | 1 |
| George, S | 1 |
| Keller, A | 1 |
| Ballester, O | 1 |
| Kovacs, M | 1 |
| Blacklock, H | 1 |
| Bell, R | 1 |
| Simeone, JF | 1 |
| Reitsma, DJ | 1 |
| Heffernan, M | 1 |
| Seaman, J | 1 |
| Knight, RD | 1 |
| Seymour, JF | 1 |
| Reeves, HL | 1 |
| Francis, RM | 1 |
| Manas, DM | 1 |
| Hudson, M | 1 |
| Day, CP | 1 |
| Sellers, E | 1 |
| Sharma, A | 1 |
| Rodd, C | 1 |
| Chapurlat, R | 1 |
| Meunier, PJ | 1 |
| Dranitsaris, G | 1 |
| MacGowan, JR | 1 |
| Pringle, J | 1 |
| Morris, VH | 1 |
| Stamp, TC | 1 |
| Shaw, NJ | 1 |
| Boivin, CM | 1 |
| Crabtree, NJ | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Diel, IJ | 1 |
| Solomayer, EF | 1 |
| Bastert, G | 1 |
| Aström, E | 1 |
| Söderhäll, S | 1 |
| Gallacher, SJ | 1 |
| Fenner, JA | 1 |
| Anderson, K | 1 |
| Bryden, FM | 1 |
| Banham, SW | 1 |
| Logue, FC | 1 |
| Cowan, RA | 1 |
| Boyle, IT | 1 |
| van Holten-Verzantvoort, AT | 1 |
| Bijvoet, OL | 1 |
| Cleton, FJ | 1 |
| Hermans, J | 1 |
| Kroon, HM | 1 |
| Harinck, HI | 1 |
| Vermey, P | 1 |
| Elte, JW | 1 |
| Neijt, JP | 1 |
| Beex, LV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631] | Phase 2 | 80 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 reviews available for pamidronate and Fracture, Pathologic
| Article | Year |
|---|---|
Long-Term Bisphosphonate Therapy in Osteogenesis Imperfecta.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Spontaneous; Humans; Imid | 2017 |
[Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Female; Fractures, Spontaneous | 2009 |
Bone-targeted agents: preventing skeletal complications in prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Tria | 2012 |
[Pamidronate in the treatment of bone metastases from breast cancer].
Topics: Ambulatory Care; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; D | 2002 |
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates; | 2002 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphon | 2006 |
Rationale for the use of bisphosphonates in breast cancer.
Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon | 1996 |
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D | 2000 |
8 trials available for pamidronate and Fracture, Pathologic
| Article | Year |
|---|---|
Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2003 |
Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.
Topics: Bone Density; Case-Control Studies; Child; Diphosphonates; Female; Fractures, Spontaneous; Humans; M | 2005 |
Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
Topics: Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Child, Preschool; Diphosp | 2006 |
Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; Diphosphonates; Female; | 2007 |
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic; | 1996 |
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
Topics: Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Spontaneous; H | 1998 |
Pamidronate for the prevention of skeletal-related events in multiple myeloma. What does the public think it is worth?
Topics: Antineoplastic Agents; Attitude to Health; Canada; Cost-Benefit Analysis; Diphosphonates; Fractures, | 1999 |
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph | 1987 |
28 other studies available for pamidronate and Fracture, Pathologic
| Article | Year |
|---|---|
Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
Topics: Absorptiometry, Photon; Adolescent; Bone Density Conservation Agents; Bone Remodeling; Child; Child, | 2014 |
Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Fem | 2016 |
[Role of an interdisciplinary approach in the healing of long bone fractures in patients with osteogenesis imperfecta].
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Femor | 2008 |
Bisphosphonate-associated osteonecrosis of the jaw: successful treatment at 2-year follow-up.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Debrideme | 2008 |
Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Comorbidi | 2010 |
Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study.
Topics: Aged; Alcohol Drinking; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Chroni | 2010 |
Outcome after repair of a sarcoma-related pathologic fracture in dogs: a Veterinary Society of Surgical Oncology Retrospective Study.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Dogs; Doxorubicin; Fema | 2011 |
Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.
Topics: Adolescent; Analgesics; Bone Density Conservation Agents; Child; Diphosphonates; Drug Evaluation; Fe | 2011 |
Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Bre | 2013 |
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles | 2002 |
Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Diphosphonates; Female; Fractures, Spontaneou | 2002 |
Bisphosphonates in prostate cancer: where are we and where should we go?
Topics: Administration, Oral; Androgen Antagonists; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone | 2003 |
Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Bone Diseases, Metabolic; Child; Child, Preschool; Diphosphona | 2004 |
Can bisphosphonate treatment be stopped in a growing child with skeletal fragility?
Topics: Accidental Falls; Bone Density; Bone Density Conservation Agents; Child, Preschool; Diphosphonates; | 2007 |
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.
Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density | 2007 |
Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.
Topics: Adolescent; Bone Diseases; Diphosphonates; Female; Femur; Follow-Up Studies; Fractures, Spontaneous; | 1994 |
Pamidronate disodium reduces skeletal complications of multiple myeloma.
Topics: Bone Diseases; Diphosphonates; Fractures, Spontaneous; Humans; Multiple Myeloma; Osteolysis; Pamidro | 1996 |
Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
Topics: Adolescent; Diphosphonates; Fractures, Spontaneous; Humans; Hypercalcemia; Male; Osteogenesis Imperf | 1997 |
[The efficacy of pamidronate in reducing skeletal associated events in patients with advanced multiple myeloma].
Topics: Diphosphonates; Fractures, Spontaneous; Humans; Infusions, Intravenous; Multiple Myeloma; Pamidronat | 1997 |
Long-term pamidronate in multiple myeloma.
Topics: Antineoplastic Agents; Diphosphonates; Female; Fractures, Spontaneous; Humans; Male; Multiple Myelom | 1998 |
Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Topics: Absorptiometry, Photon; Adult; Aged; Bone Density; Diphosphonates; Female; Follow-Up Studies; Fractu | 1998 |
The use of pamidronate in three children with renal disease.
Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; | 1998 |
The nonsurgical treatment of fibrous dysplasia.
Topics: Adolescent; Bone Density; Calcium; Diphosphonates; Ergocalciferols; Female; Fibrous Dysplasia of Bon | 1999 |
Gross vertebral collapse associated with long-term disodium etidronate treatment for pelvic Paget's disease.
Topics: Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Arthralgia; Diphosphonates; Etidronic Acid; Fo | 2000 |
Intravenous pamidronate in juvenile osteoporosis.
Topics: Absorptiometry, Photon; Acute-Phase Reaction; Adolescent; Bone Density; Child; Diphosphonates; Femal | 2000 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone Density; Bone Remodeling; Child; Child, Prescho | 2002 |
Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Topics: Adult; Aged; Asthma; Bone Density; Cervical Vertebrae; Diphosphonates; Female; Femur; Fractures, Spo | 1992 |